Efficacy and safety of anti-VEGF drugs in the treatment of non-arteritic anterior ischemic optic neuropathy: a multiple center, randomized, controlled trial

A multiple center, randomized, controlled trial for efficacy and safety of anti-VEGF drugs in the treatment of non-arteritic anterior ischemic optic neuropathy

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000028732

Enrollment

Unknown

Registered

2020-01-01

Start date

2018-01-01

Completion date

Unknown

Last updated

2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-arteritic anterior ischemic optic neuropathy

Interventions

Experimental group:Lucentis intravitreal injection

Control group:Simulation of intravitreal injection

Eligibility

Sex/Gender

All

Age

40 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. NAION diagnosis; 2. Aged 40-65 years; 3. Gender limitation; 4. Best corrected vision acuity 0.1-0.8.

Exclusion criteria

Exclusion criteria: 1. Other eye diseases; 2. Eye surgery; 3. Received similar medication; 4. Systemic diseases: cardiopulmonary dysfunction; 5. Pregnant women, etc.

Design outcomes

Primary

Measure	Time frame
BCVA;	—

Countries

China

Contacts

Public ContactShihui Wei

the First Medical Center of Chinese PLA General Hospital

weishihui706@hotmail.com+86 13910079431

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026